TL;DR
This systematic review and meta-analysis consolidates evidence from 14 studies, revealing a strong association between abnormal β-catenin expression and bladder cancer (BC). Higher β-catenin levels correlate with more aggressive tumor characteristics, poorer prognosis, and shorter progression-free survival, suggesting its potential as a valuable biomarker for BC malignancy and outcome.
What Problem Does This Paper Address?
Bladder cancer (BC) is a significant global health concern, characterized by complex etiology and varied clinical outcomes. While some studies have suggested a link between the aberrant expression of β-catenin and BC progression and survival, these findings have been inconsistent, leading to uncertainty. This paper aims to resolve these controversies by systematically reviewing and meta-analyzing existing literature to establish a clearer, evidence-based understanding of β-catenin's predictive value in BC. This is crucial for identifying potential biomarkers that can aid in diagnosis, treatment, and prognosis.
Methods
The researchers conducted a systematic literature search across multiple databases (Embase, PubMed, Cochrane Library, Science Direct/Elsevier, Medline, and CNKI) up to March 2020 to identify relevant studies. They included studies that investigated the correlation between β-catenin expression and BC, focusing on full-text documents. A meta-analysis was then performed using Review Manager and Stata software. This involved calculating combined Odds Ratios (ORs) with 95% confidence intervals (CIs) using random- or fixed-effects models, depending on heterogeneity. Heterogeneity was assessed using P-values and the I-square statistic. Publication bias was evaluated using funnel plots and Egger's regression test.
Datasets
The study did not introduce new datasets. Instead, it analyzed data from 14 previously published studies. These studies collectively included 865 bladder cancer (BC) tissues and 106 control (normal bladder) tissues. The data extracted from these studies pertained to the aberrant expression rates of β-catenin in various BC subtypes and their correlation with clinical outcomes.
Key Insights and Ideas
- β-catenin as a "red flag" for BC: The meta-analysis strongly supports that elevated β-catenin levels are not just present in BC but are significantly higher compared to normal bladder tissues. This suggests β-catenin plays a direct role in the development or progression of the disease.
- Aggression marker: The findings highlight that β-catenin's aberrant expression is particularly pronounced in more aggressive forms of BC – high-grade and invasive tumors. This implies that β-catenin could help differentiate between less and more dangerous BC subtypes.
- Prognostic indicator: The study provides compelling evidence that higher β-catenin expression is linked to a worse prognosis, specifically a shorter progression-free survival (PFS). This makes β-catenin a potential tool for predicting how a patient's BC might behave over time.
- Consolidating conflicting evidence: By pooling data from multiple studies, this meta-analysis offers a more robust conclusion than individual studies, helping to resolve previous inconsistencies regarding β-catenin's role in BC.
Key Results
- BC vs. Normal Tissues: Aberrant β-catenin expression was significantly increased in BC tissues compared to normal bladder tissues, with a combined OR of 14.69 [5.73, 37.65] (P<0.05).
- Grade and Stage:
- High-grade BC tissues showed significantly higher aberrant β-catenin expression than low-grade tissues, with a combined OR of 0.31 [0.23, 0.43] (P<0.05).
- Invasive BC tissues also showed significantly higher aberrant β-catenin expression than non-muscle-invasive (superficial) tissues, with a combined OR of 0.21 [0.15, 0.29] (P<0.05).
- Prognosis: Higher β-catenin expression levels were associated with shorter progression-free survival (PFS) in BC patients, with a combined OR of 2.74 [1.22, 6.14] (P<0.05).
- Publication Bias: Begg's funnel plots and Egger's regression tests indicated no significant publication bias in the meta-analysis.
Limitations and Future Work
The authors acknowledge several limitations:
- Small Sample Size: The total number of included studies (14) and the combined sample size (865 BC tissues, 106 controls) are relatively small for definitive conclusions.
- Lack of Prospective Research: The included studies were primarily case-control, which inherently have lower levels of evidence compared to randomized controlled trials (RCTs) or cohort studies.
- Incomplete Literature Data: Some literature data were incomplete, leading to the exclusion of potentially relevant studies.
Future work should focus on large-scale, prospective studies to further validate these findings and solidify β-catenin's role as a clinical biomarker for BC. More in-depth research is needed to fully elucidate the complex relationship between β-catenin and BC.
Summary updated